A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2

• DOI: 10.1007/s13277-013-1025-3
• Publication Date: 2013-07-29T00:42:50Z
• Authors: Yan Wang; Jingyi Ma; Sheung Ching Chow; Chi Han Li; Zhangang Xiao; Ru Feng; Jie Fu; Yangchao Chen
• Keywords: Viability assay

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and third cause of cancer-related deaths. Currently available treatment options for HCC patients are scarce resulting in an urgent need to develop a novel effective cure. Polygonum capitatum medicinal herb which has been used treat inflammatory diseases Miao nationality China. We recently isolated pure compound davidiin from P. extract. Four cell lines were treated with davidiin. Cell viability was recorded by MTT assay. siRNAs targeting enhancer zeste homolog 2 (EZH2) applied modulate expression EZH2. Established xenograft mice models evaluate vivo anticancer activity investigated underlying mechanism The inhibited growth also suppressed tumor xenografted mouse. Such inhibition facilitated specifically downregulation on possesses both vitro warrants further clinical investigation as potential anti-HCC agent.